Email Alert | RSS

北京大学学报（医学版） ›› 2019, Vol. 51 ›› Issue (1): 35-42. doi: 10.19723/j.issn.1671-167X.2019.01.007

• 论著 • 上一篇    下一篇

原发性腮腺淋巴瘤的临床病理特点及预后分析

宿骞1,彭歆1,周传香2,△(),俞光岩1,△()   

  1. 1. 北京大学口腔医学院·口腔医院,口腔颌面外科,北京　100081
    2. 北京大学口腔医学院·口腔医院, 病理科　国家口腔疾病临床医学研究中心　口腔数字化医疗技术和材料国家工程实验室　口腔数字医学北京市重点实验室,北京　100081
  • 收稿日期:2018-10-15 出版日期:2019-02-18 发布日期:2019-02-26
  • 通讯作者: 周传香,俞光岩 E-mail:zhoucx2008@126.com;gyyu@263.net

Clinicopathological features and possible prognostic factors in parotid lymphomas

Qian SU1,Xin PENG1,Chuan-xiang ZHOU2,△(),Guang-yan YU1,△()   

  1. 1. Department of Oral and Maxillofacial Surgery, Beijing 100081, China
    2. Department of Oral Pathology, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
  • Received:2018-10-15 Online:2019-02-18 Published:2019-02-26
  • Contact: Chuan-xiang ZHOU,Guang-yan YU E-mail:zhoucx2008@126.com;gyyu@263.net

RICH HTML

 37   

PDF (PC)

333

摘要：

目的: 探讨原发性腮腺淋巴瘤的临床病理特点及影响其预后的因素。方法: 收集2006—2016年于北京大学口腔医院口腔颌面外科就诊并诊断为原发性腮腺淋巴瘤患者的相关临床资料,结合复查随访资料,回顾性总结其临床病理特点及患者预后,分析影响预后的相关因素。结果:研究共纳入41例患者,中位年龄57岁(8个月至91岁),男 ∶女=1 ∶2.15,女性多见。40例(97.1%)为非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL),其中结外边缘区黏膜相关淋巴组织淋巴瘤(extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,MALT)15例,弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)14例,滤泡型淋巴瘤(follicular lymphoma,FL)4例,其他类型少见,霍奇金淋巴瘤(Hodgkin lymphoma,HL)仅占1例。Ann Arbor ⅠE~ⅡE期37例(90.2%),ⅢE~ⅣE期4例(9.8%)。7例(17.1%)淋巴瘤由干燥综合征恶变而来,均为MALT淋巴瘤。平均病期为20.7月,78%的患者以腮腺区缓慢生长的无痛性肿块为主要症状。治疗方法包括局部治疗及系统治疗,不同治疗方案均可取得较好疗效。全部患者均经5~149个月随访,其中9例(21.9%)死亡,2年总生存率为84.5%,5年总生存率为81.3%。单因素分析显示有无肿物加速生长史(P=0.005)和肿物有无包膜(P=0.011)为总生存率的影响因素,多因素分析显示肿物有无包膜(P=0.041)影响患者的总生存期。结论:腮腺淋巴瘤绝大多数为B细胞型NHL,MALT淋巴瘤与DLBCL最为常见,大部分患者表现为缓慢生长的腮腺区局限性肿块,临床上需与腮腺良性肿瘤相鉴别。干燥综合征与MALT淋巴瘤的发病密切相关。原发性腮腺淋巴瘤患者预后比其他恶性肿瘤相对较好,肿物无包膜提示预后较差。

关键词: 淋巴瘤, 腮腺, 临床病理, 预后

Abstract:

Objective: To investigate the clinicopathological features and prognostic factors in lymphoma of parotid origin. Methods: Clinicopathological data of the patients with parotid lymphoma who were initially diagnosed in Peking University Hospital of Stomatology from 2006 to 2016 were collected and analyzed retrospectively. The patients were followed-up for 5 to 149 months with a median period of 45 months, and the factors influencing the prognosis were evaluated. Results: A total of 41 patients with primary parotid lymphoma were included in this retrospective study. The rate of male to female was 1 ∶2.15. The median age was 57 years (ranging from 8 months to 91 years). According to WHO classification, 40 cases (97.1%) were diagnosed as non-Hodgkin lymphoma (NHL), including 15 cases of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), 14 cases of diffuse large B cell lymphoma (DLBCL) as well as 4 cases of follicular lymphoma, while other subtypes of NHL were rare. Only one case was diagnosed as Hodgkin lymphoma. Regarding the clinical staging at the initial diagnosis, 37 patients (90.2%) were diagnosed as stage ⅠE or ⅡE of the disease, while 4 patients (9.8%) as stage ⅢE or stage ⅣE. Seven patients (17.1%) had a history of Sjögren syndrome (SS), all of whom were MALT lymphoma. The mean ill duration of the 41 patients were 20.7 months. Thirty-two patients (78%) presented a slowly growing painless mass in the parotid gland. Treatment options included localized therapy and systemic therapy, all of whom had good curative effect. Nine patients (21.9%) died during the follow-up period. The overall survival rates of 2-year and 5-year were 84.5% and 81.3% respectively. The univariate analysis demonstrated statistically significant differences for accelerated growth of tumor (P=0.005), and presence of tumor capsule (P=0.011). The multi-univariate analysis demonstrated statistically significant differences for presence of tumor capsule (P=0.041). Conclusion: A large majority of primary parotid lymphoma were NHL, among which MALT lymphoma and DLBCL were common subtypes. Most patients presented an indolent mass in parotid gland, which should be distinguished from the parotid benign tumors. SS is closely related to the pathogenesis of MALT lymphoma. The prognosis is better than that of other malignant parotid tumors. Absence of tumor capsule may predict a poor prognosis in patients with parotid lymphoma.

Key words: Lymphoma, Parotid gland, Clinical pathology, Prognosis

中图分类号: 

  • R733.41

表1

41例腮腺淋巴瘤患者的临床特点"

Clinical features n (%)
Gender
Female 28 (68.3)
Male 13 (31.7)
Age
≥60 years 23 (56.1)
<60 years 18 (43.9)
Accelerated growth of tumor 11 (26.8)
Tumors without capsule 15 (36.6)
Extent
Unilateral 36 (87.8)
Bilateral 5 (12.2)
Location
Superficial lobe 38 (92.7)
Deep lobe 3 (7.3)
Histologic classification
MALT 15 (36.6)
DLBCL 14 (34.1)
FL 4 (9.7)
LL 2 (4.9)
LBL 2 (4.9)
Other NHL 3 (7.3)
HL 1 (2.4)
Ann Arbor stage
Stage Ⅰ and Ⅱ 37 (90.2)
Stage Ⅲ and Ⅳ 4 (9.8)
Autoimmune disorders 8 (19.5)
Sjögren syndrome 7 (17.1)
Rheumatoid arthritis 1 (2.4)
Cervical lymph node enlargement 12 (34.3)
Local symptoms 9 (22.0)
Spontaneous pain 9 (22.0)
Facial paralysis 2 (4.8)
Special infection 4 (9.8)
HCV 1 (2.4)
HBV 3 (7.3)
HIV 0
Elevated LDH level 1 (2.4)
B symptoms 0

图1

腮腺黏膜相关淋巴组织淋巴瘤"

图2

腮腺滤泡淋巴瘤"

图3

41例腮腺淋巴瘤的治疗情况统计"

图4

41例腮腺淋巴瘤生存曲线"

表2

原发性腮腺淋巴瘤影响生存率的单因素分析"

Risk factor 2-year
OS/%		 5-year
OS/%		 Log-rank
χ2		 P according to
Log-rank		 HR (95%CI) P according to Cox
Gender 0.014 0.907 0.960 (0.479-1.922) 0.907
Female 84.6 84.6
Male 84.5 79.5
Age 4.128 0.042 0.475 (0.216-1.043) 0.063
≥60 years 76.2 69.8
<60 years 90.9 90.9
Accelerated growth of tumor 7.846 0.005 5.446 (1.446-20.516) 0.012
Yes 47.7 47.7
No 96.0 90.9
Location 1.825 0.177 4.005 (0.455-35.283) 0.211
Superficial lobe 86.3 83.0
Deep lobe 50.0 50.0
Local symptoms 2.414 0.120 3.004 (0.701-12.876) 0.138
Yes 57.1 57.1
No 90.2 86.1
Histologic classification 0.843 0.359 0.697 (0.317-1.532) 0.369
MALT 92.3 83.1
Other subtypes 80.0 80.0
Ann Arbor stage 2.480 0.115 0.545 (0.224-1.216) 0.138
Stage Ⅰ and Ⅱ 85.9 82.3
Stage Ⅲ and Ⅳ 66.7 66.7
Sjögren syndrome 0.383 0.536 0.5203 (0.065-4.224) 0.543
Yes 81.5 81.5
No 100 83.3
Surgery 0.270 0.603 0.660 (0.136-3.206) 0.606
Yes 87.0 83.1
No 75.0 75.0
Tumor capsule 6.410 0.011 0.131 (0.026-0.653) 0.013
Yes 95.2 63.0
No 77.9 64.9

表3

腮腺淋巴瘤影响生存率因素的多因素分析"

Risk factor HR (95%CI) P
Accelerated growth of tumor (Yes/No) 3.715
(0.943-14.632)		 0.061
Tumor capsule (Yes/No) 0.178
(0.034-0.932)		 0.041

图5

肿物是否存在包膜的多因素生存分析"

[1] 陈万青, 郑荣寿, 张思维 , 等. 2013年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2017,26(1):1-7.
[2] 李小秋, 李甘地, 高子芬 , 等. 中国淋巴瘤亚型分布:国内多中心性病例10 002例分析[J]. 诊断学理论与实践, 2012,11(2):111-115.
doi: 10.3969/j.issn.1671-2870.2012.02.006
[3] Urquhart A, Berg R . Hodgkin’s and non-Hodgkin’s lymphoma of the head and neck[J]. Laryngoscope, 2001,111(9):1565-1569.
doi: 10.1097/00005537-200109000-00013 pmid: 11568605
[4] Etemad-Moghadam S, Tirgary F, Keshavarz S , et al. Head and neck non-Hodgkin’s lymphoma: a 20-year demographic study of 381 cases[J]. Int J Oral Max Surg, 2010,39(9):869-872.
doi: 10.1016/j.ijom.2010.03.029 pmid: 20538427
[5] Swerdlow SH, Campo E, Harris NL , et al. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. 4th ed. Iyon: International Agency for Research on Cancer, 2017.
[6] Skarin AT, Dorfman DM . Non-Hodgkin’s lymphomas: Current classification and management[J]. CA Cancer J Clin, 1997,47(6):351-372.
doi: 10.3322/canjclin.47.6.351 pmid: 9371057
[7] Gleeson MJ, Bennett MH, Cawson RA . Lymphomas of salivary glands[J]. Cancer, 1986,58(3):699-704.
doi: 10.1002/(ISSN)1097-0142
[8] El-Naggar AK, Chan JKC, Grandis JR , et al. WHO classification of head and neck tumors[M]. 4th ed. Lyon: International Agency for Research on Cancer, 2017: 276-280.
[9] Feinstein AJ, Ciarleglio MM, Cong X , et al. Parotid gland lymphoma: prognostic analysis of 2140 patients[J]. Laryngoscope, 2013,123(5):1199-1203.
doi: 10.1002/lary.23901 pmid: 23576299
[10] Vazquez A, Khan MN, Sanghvi S , et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a population-based study from 1994 to 2009[J]. Head Neck, 2015,37(1):18-22.
doi: 10.1002/hed.23543 pmid: 24733777
[11] Isaacson P, Wright DH . Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma[J]. Cancer, 1983,52(8):1410-1416.
doi: 10.1002/(ISSN)1097-0142
[12] 徐鹏程, 周心一, 周晨 , 等. 腮腺黏膜相关淋巴组织淋巴瘤的临床特点分析[J]. 临床耳鼻咽喉头颈外科杂志, 2017(1):61-64.
[13] Ambrosetti A, Zanotti R, Pattaro C , et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associa-ted either with Sjögren syndrome or hepatitis C virus infection[J]. Br J Haematol, 2004,126(1):43-49.
doi: 10.1111/j.1365-2141.2004.04993.x pmid: 15198730
[14] Dong L, Chen Y, Masaki Y , et al. Possible mechanisms of lymphoma development in Sjögren’s syndrome[J]. Curr Immunol Rev, 2013,9(1):13-22.
doi: 10.2174/1573395511309010003
[15] Zhang W, Feng S, Yan S , et al. Incidence of malignancy in primary Sjögren’s syndrome in a Chinese cohort[J]. Rheumatology (Oxford), 2010,49(3):571-577.
doi: 10.1093/rheumatology/kep404 pmid: 20040528
[16] Theander E, Henriksson G, Ljungberg O , et al. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors[J]. Ann Rheum Dis, 2006,65(6):796-803.
doi: 10.1136/ard.2005.041186 pmid: 1798187
[17] 卢松鹤, 闫志敏, 魏明洁 , 等. 结节型舍格伦综合征与恶性淋巴瘤关系初探[J]. 中华口腔医学杂志, 2012,47(4):208-213.
doi: 10.3760/cma.j.issn.1002-0098.2012.04.004
[18] Peveling-Oberhag J, Arcaini L, Bankov K , et al. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis[J]. J Viral Hepat, 2016,23(7):536-544.
doi: 10.1111/jvh.12518 pmid: 26924533
[19] Arcaini L, Rossi D, Lucioni M , et al. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection[J]. Haematologica, 2015,100(2):246-252.
doi: 10.3324/haematol.2014.116855 pmid: 25381127
[20] Brito-Zerón P, Gheitasi H, Retamozo S , et al. How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients[J]. Arthritis Res, 2015,17(1):1-9.
doi: 10.1186/s13075-014-0514-0 pmid: 4318544
[21] Raderer M, Kiesewetter B, Ferreri AJ . Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)[J]. CA Cancer J Clin, 2016,66(2):153-171.
doi: 10.3322/caac.21330 pmid: 26773441
[22] Swerdlow SH, Campo E, Pileri SA , et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016,127(20):2375-2390.
doi: 10.1182/blood-2016-01-643569
[23] Thielker J, Grosheva M, Ihrler S , et al. Contemporary management of benign and malignant parotid tumors[J]. Front Surg, 2018,39(5):1-17.
doi: 10.3389/fsurg.2018.00039
[24] Gudmundsson JK, Ajan A, Abtahi J . The accuracy of fine-needle aspiration cytology for diagnosis of parotid gland masses: a clinicopathological study of 114 patients[J]. J Appl Oral Sci, 2016,24(6):561-567.
doi: 10.1590/1678-775720160214 pmid: 5161254
[25] Orita Y, Sato Y, Kimura N , et al. Characteristic ultrasound features of mucosa-associated lymphoid tissue lymphoma of the salivary and thyroid gland[J]. Acta Otolaryngol, 2014,134(1):93-99.
doi: 10.3109/00016489.2013.831994 pmid: 24256049
[26] 高润涛, 耿雪霏 . 8例腮腺恶性淋巴瘤诊疗体会[J]. 口腔医学研究, 2017,33(8):870-873.
doi: 10.13701/j.cnki.kqyxyj.2017.08.017
[27] Olszewski AJ, Desai A . Radiation therapy administration and survival in stage Ⅰ/Ⅱ extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue[J]. Int J Radiat Oncol Biol Phys, 2014,88(3):642-649.
doi: 10.1016/j.ijrobp.2013.11.225 pmid: 24411627
[28] Jackson AE, Mian M, Kalpadakis C , et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a multicenter, international experience of 248 patients (IELSG 41)[J]. Oncologist, 2015,20(10):1149-1153.
doi: 10.1634/theoncologist.2015-0180 pmid: 26268740
[29] Salles G, Barrett M, Foa R , et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience[J]. Adv Ther, 2017,34(10):2232-2273.
doi: 10.1007/s12325-017-0612-x pmid: 5656728
[30] 傅志英, 朱军, 宋玉琴 , 等. 525例弥漫大B细胞淋巴瘤预后影响因素分析[J]. 北京大学学报(医学版), 2014,46(3):405-411.
doi: 10.3969/j.issn.1671-167X.2014.03.013
[31] 杨小芸, 沈丽达, 龙庭凤 , 等. 1 326例非霍奇金淋巴瘤临床病理特点分析[J]. 中华肿瘤防治杂志, 2016,23(9):605-609.
[1] 俞光岩,柳登高,李巍,洪霞,张严妍,朱文瑄,张可夫,李潇,栗占国,刘燕鹰,陈艳,高岩,苏家增. 3类新型慢性唾液腺炎的诊断和治疗[J]. 北京大学学报（医学版）, 2022, 54(1): 13-17.
[2] 陈超伦,苏家增,俞光岩. 酸刺激对腮腺和下颌下腺唾液流率及成分的影响[J]. 北京大学学报（医学版）, 2022, 54(1): 89-94.
[3] 王飞,朱翔,贺蓓,朱红,沈宁. 自发缓解的滤泡性细支气管炎伴非特异性间质性肺炎1例报道并文献复习[J]. 北京大学学报（医学版）, 2021, 53(6): 1196-1200.
[4] 高伟波,石茂静,张海燕,吴春波,朱继红. 显著高铁蛋白血症与噬血细胞性淋巴组织细胞增多症的相互关系[J]. 北京大学学报（医学版）, 2021, 53(5): 921-927.
[5] 张梅香,史文芝,刘建新,王春键,李燕,王蔚,江滨. MLL-AF6融合基因阳性急性髓系白血病的临床特征及预后[J]. 北京大学学报（医学版）, 2021, 53(5): 915-920.
[6] 蒋艳芳,王健,王永健,刘佳,裴殷,刘晓鹏,敖英芳,马勇. 前交叉韧带翻修重建术后中长期临床疗效及影响因素[J]. 北京大学学报（医学版）, 2021, 53(5): 857-863.
[7] 肖若陶,刘承,徐楚潇,何为,马潞林. 术前血小板参数与局部进展期肾细胞癌预后[J]. 北京大学学报（医学版）, 2021, 53(4): 647-652.
[8] 于妍斐,何世明,吴宇财,熊盛炜,沈棋,李妍妍,杨风,何群,李学松. 延胡索酸水合酶缺陷型肾细胞癌的临床病理特征及预后[J]. 北京大学学报（医学版）, 2021, 53(4): 640-646.
[9] 赵勋,颜野,黄晓娟,董靖晗,刘茁,张洪宪,刘承,马潞林. 癌栓粘连血管壁对非转移性肾细胞癌合并下腔静脉癌栓患者手术及预后的影响[J]. 北京大学学报（医学版）, 2021, 53(4): 665-670.
[10] 陈怀安,刘硕,李秀君,王哲,张潮,李凤岐,苗文隆. 炎症生物标志物对输尿管尿路上皮癌患者预后预测的临床价值[J]. 北京大学学报（医学版）, 2021, 53(2): 302-307.
[11] 廖栩鹤,王荣福,刘萌,陈雪祺,熊焰,农琳,殷雷,张炳晔,杜毓菁. 18F-FDG PET/CT半定量参数、表皮生长因子受体和间变淋巴瘤激酶基因突变对肺腺癌患者预后评估的价值[J]. 北京大学学报（医学版）, 2021, 53(2): 246-254.
[12] 俞光岩. 多发性唾液腺肿大的鉴别诊断及处理[J]. 北京大学学报（医学版）, 2021, 53(1): 1-4.
[13] 池彦廷,张延平,张秋露,刘翠苓,李斌斌. 唾液腺干燥综合征继发黏膜相关淋巴组织淋巴瘤的临床病理分析[J]. 北京大学学报（医学版）, 2021, 53(1): 40-45.
[14] 刘世博,高辉,冯元春,李静,张彤,万利,刘燕鹰,李胜光,罗成华,张学武. 腹膜后纤维化致肾盂积水的临床分析:附17例报道[J]. 北京大学学报（医学版）, 2020, 52(6): 1069-1074.
[15] 程功,张霞,杨菲,程嘉渝,刘燕鹰. 以发热、关节炎、皮肤色素沉着为主要表现的血管免疫母细胞性T细胞淋巴瘤1例[J]. 北京大学学报（医学版）, 2020, 52(6): 1150-1152.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 田增民, 陈涛, Nanbert ZHONG, 李志超, 尹丰, 刘爽. 神经干细胞移植治疗遗传性小脑萎缩的临床研究（英文稿）[J]. 北京大学学报（医学版）, 2009, 41(4): 456 -458 .
[2] 郭岩, 谢铮. 用一代人时间弥合差距——健康社会决定因素理论及其国际经验[J]. 北京大学学报（医学版）, 2009, 41(2): 125 -128 .
[3] 卢恬, 朱晓辉, 柳世庆, 郑杰, 邱晓彦. 白细胞介素2促进宫颈癌细胞系HeLaS3免疫球蛋白G的表达[J]. 北京大学学报（医学版）, 2009, 41(2): 158 -161 .
[4] 袁惠燕, 张苑, 范田园. 离子交换型栓塞微球及其载平阳霉素的制备与性质研究[J]. 北京大学学报（医学版）, 2009, 41(2): 217 -220 .
[5] 徐莉, 孟焕新, 张立, 陈智滨, 冯向辉, 释栋. 侵袭性牙周炎患者血清中抗牙龈卟啉单胞菌的IgG抗体水平的研究[J]. 北京大学学报（医学版）, 2009, 41(1): 52 -55 .
[6] 董稳, 刘瑞昌, 刘克英, 关明, 杨旭东. 氯诺昔康和舒芬太尼用于颌面外科术后自控静脉镇痛的比较[J]. 北京大学学报（医学版）, 2009, 41(1): 109 -111 .
[7] 祁琨, 邓芙蓉, 郭新彪. 纳米二氧化钛颗粒对人肺成纤维细胞缝隙连接通讯的影响[J]. 北京大学学报（医学版）, 2009, 41(3): 297 -301 .
[8] Jian-wei GU, Emily YOUNG, Zhi-jun PAN, Kevan B. TUCKER, Megan SHPARAGO, Min HUANG, Amelia Purser BAILEY. SD大鼠长期高盐饮食可导致其高血压并改变肾细胞因子基因表达谱[J]. 北京大学学报（医学版）, 2009, 41(5): 505 -515 .
[9] 李宏亮*, 安卫红*, 赵扬玉, 朱曦. 妊娠合并高脂血症性胰腺炎行血液净化治疗1例[J]. 北京大学学报（医学版）, 2009, 41(5): 599 -601 .
[10] 李伟军, 邢晓芳, 曲立科, 孟麟, 寿成超. PRL-3基因C104S位点突变体和CAAX缺失体的构建及表达[J]. 北京大学学报（医学版）, 2009, 41(5): 516 -520 .
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部